San Diego-based NuVasive reported its financial results for the fourth quarter and full-year 2016.
Here are 10 report highlights:
1. In Q4 2016, NuVasive's revenue totaled $271.1 million, reflecting a 25.9 percent boost from the same period the year prior.
2. NuVasive's gross profit totaled $204.2 million in Q4 2016, on a GAAP and non-GAAP basis.
3. The company's GAAP operating profit margin was 11.1 percent in Q4 2016, with a non-GAAP operating profit margin of 18 percent.
4. NuVasive witnessed GAAP diluted earnings per share of $0.11, and non-GAAP diluted earnings per share of $0.53.
5. NuVasive saw revenue of $962.1 million for the full year of 2016, an 18.6 percent increase from full-year 2015.
6. The company's GAAP gross profit totaled $722 million and non-GAAP gross profit was $736.7 million for the full-year 2016.
7. The full-year 2016 GAAP operating profit margin was 12.8 percent, with a non-GAAP operating profit margin of 16.1 percent.
8. The company saw GAAP diluted earnings per share of $0.69 for the full-year 2016, and non-GAAP diluted earnings per share of $1.66.
9. NuVasive's cash, cash equivalents and short and long-term marketable securities totaled about $153.6 million by Dec. 31, 2016.
10. In 2017, the company will look to expand its spine deformity presence, boost in-sourced manufacturing and streamline operations.
"NuVasive delivered record fourth quarter results and exceeded expectations for the full year 2016. By all measures, the company had a tremendous year executing against our market-share taking initiatives, delivering strong revenue growth, including a return to 20% year-over-year growth in our core international markets," said Gregory T. Lucier, chairman and CEO of NuVasive.